Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial

Sebastian Michels, Bartomeu Massuti, Hans-Ulrich Schildhaus, Jeremy Franklin, Martin Sebastian, Enriqueta Felip, Christian Grohe, Delvys Rodriguez-Abreu, Diana S. Y. Abdulla, Helge Bischoff, Christian Brandts, Enric Carcereny, Jesus Corral, Anne-Marie C. Dingemans, Eva Pereira, Jana Fassunke, Rieke N. Fischer, Masyar Gardizi, Lukas Heukamp, Amelia InsaAnna Kron, Roopika Menon, Thorsten Persigehl, Martin Reck, Richard Riedel, Sacha I. Rothschild, Andreas H. Scheel, Matthias Scheffler, Petra Schmalz, Egbert F. Smit, Meike Limburg, Mariano Provencio, Niki Karachaliou, Sabine Merkelbach-Bruse, Martin Hellmich, Lucia Nogova, Reinhard Buettner, Rafael Rosell, Juergen Wolf*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1266-1276
Number of pages11
JournalJournal of Thoracic Oncology
Volume14
Issue number7
DOIs
Publication statusPublished - Jul 2019

Keywords

  • Lung cancer
  • Targeted treatment
  • ROS1
  • Crizotinib
  • TP53
  • ROS1 REARRANGEMENTS
  • ANAPLASTIC LYMPHOMA
  • ANTITUMOR-ACTIVITY
  • KINASE INHIBITION
  • TARGETING ROS1
  • ALK
  • ADENOCARCINOMA
  • CHEMOTHERAPY
  • MUTATIONS
  • FUSIONS

Cite this